AGPAT2 Antikörper (AA 121-220)

Produktnummer ABIN708656

Produktdetails anti-AGPAT2 Antikörper

Target: AGPAT2 (1-Acylglycerol-3-Phosphate O-Acyltransferase 2 (Lysophosphatidic Acid Acyltransferase, Beta) (AGPAT2))

Bindungsspezifität: AA 121-220

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AGPAT2 Antikörper ist unkonjugiert

Applikation: ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Homologie: Human,Mouse,Rat,Dog,Cow,Pig,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human Agpat2

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu AGPAT2

Target: AGPAT2 (1-Acylglycerol-3-Phosphate O-Acyltransferase 2 (Lysophosphatidic Acid Acyltransferase, Beta) (AGPAT2))

Andere Bezeichnung: Agpat2 (AGPAT2 Produkte)

Hintergrund:

Synonyms: LPAAB, BSCL, BSCL1, EC 2.3.1.51, LPAAB, LPAAT beta, Lysophosphatidic acid acyltransferase beta, 1 acyl sn glycerol 3 phosphate acyltransferase beta, 1 acylglycerol 3 phosphate O acyltransferase 2, 1 AGP acyltransferase 2, 1 AGPAT2 antibody Berardinelli Seip congenital lipodystrophy.PLCB_HUMAN

Background: Agpat2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. It is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Gen-ID: 10555